Drugs / Dyanavel XR
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DYANAVEL XR | — | 2015-10-19 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06248229 Comparator | Sep 2024 → Sep 2026 overdue | attention deficit-hyperactivity disorder | Rochester Center for Behavioral Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dyanavel XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06248229 ↗ |
| Route | Oral | “tablets should be swallowed whole, not crushed, chewed, or cut.” NCT06248229 ↗ |